Research programme: CNS and metabolic disorders therapeutics - BioFocus/Biovitrum

Drug Profile

Research programme: CNS and metabolic disorders therapeutics - BioFocus/Biovitrum

Alternative Names: GPCR modulators - BioFocus/Biovitrum; Serotonin 2a receptor antagonists - BioFocus/Biovitrum

Latest Information Update: 15 Apr 2014

Price : $50

At a glance

  • Originator BioFocus DPI; Biovitrum
  • Class
  • Mechanism of Action G protein-coupled receptor modulators; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued CNS disorders; Major depressive disorder; Obesity

Most Recent Events

  • 31 Mar 2014 BioFocus DPI has been acquired by Charles River Laboratories
  • 29 Jul 2005 Discontinued - Preclinical for Depression in Europe (unspecified route)
  • 29 Jul 2005 Discontinued - Preclinical for CNS disorders in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top